Skip to content

Member

Anthony SMITH

The Left · France

Group
The Left
Country
France
Roll-call participation
92.3 %ⓘ of 620 roll calls in office · chamber median 90.6 % · whole term, final votes
With majority line
91.0 %ⓘ of 567 votes where the group had a line · The Left median 86.6 %
More facts (5)
National party
LFI La France Insoumise
In office
Since 16 Jul 2024
Against clear line
13 of 478 votesⓘ
Committees
AFCO, CULT (substitute), ITRE
Member id
256910
More

Record

The member’s figures against the median of their group and of the chamber. Each vote counts the member in the group they belonged to that day.

Roll-call participation ⓘ

92.3 %

572 of 620 final votes while in office

The Left median: 86.9 % (+5.3 pts)

Chamber median: 90.6 %

With majority line ⓘ

91.0 %

516 of 567 votes where their group had a line

The Left median: 86.6 % (+4.4 pts)

Against clear line ⓘ

2.7 %

13 of 478 votes where their group had a clear line

8 opposite (for ↔ against), 4 abstained against the line, 1 voted for or against when the line was to abstain

Abstention ⓘ

13.8 %

79 of 572 votes cast

Participation 92.3 % — The Left median 86.9 %, 47 members.ⓘ
Data as a table
Participation among the 47 members of the The Left with enough votes.
FigureParticipation
Anthony SMITH92.3 %
The Left median86.9 %
Lowest in the group37.7 %
Highest in the group99.4 %
Members47
With majority line 91.0 % — The Left median 86.6 %, 47 members.ⓘ
Data as a table
With majority line among the 47 members of the The Left with enough votes.
FigureWith majority line
Anthony SMITH91.0 %
The Left median86.6 %
Lowest in the group64.5 %
Highest in the group91.8 %
Members47
  • Whole term, 620 final votes; 620 of 794 decisions had a final vote recorded by name. The dots are the other members of The Left; no ranks.
  • “No vote recorded” is not the same as absent: leave, illness and chairing the sitting look the same.
  • A group’s line is inferred from its members’ votes — Parliament publishes no whip.

Votes, 5 928

Export

Every roll-call vote of the term with the member’s position, newest first.

Result: for–against–abstained. Majority line: how most of the member’s group voted that day (“Tie” when no position won). ≠ group marks a vote otherwise than a clear line (at least two thirds, with at least 10 members voting) of their group.
DateDecision and voteResultPositionMajority line
9 Sept 2025EU-Kyrgyz Republic Enhanced Partnership and Cooperation Agreement (Resolution) Final vote — text as a wholeAdopted 434 for, 49 against, 168 abstainedPosition: Abstained Majority line: Abstained
9 Sept 2025EU-Kyrgyz Republic Enhanced Partnership and Cooperation Agreement (Resolution) Amendment 12, adding text after paragraph 12 72 for, 522 against, 51 abstainedPosition: Against Majority line: Against
9 Sept 2025EU-Kyrgyz Republic Enhanced Partnership and Cooperation Agreement Final vote on the draft Council decisionConsent given 473 for, 114 against, 58 abstainedPosition: Against Majority line: Against
9 Sept 2025EU-Brazil Agreement: cooperation with and through Europol and the Federal Police of Brazil Final vote on the draft Council decisionConsent given 606 for, 5 against, 19 abstainedPosition: Abstained Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Final votePassed 431 for, 145 against, 76 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 395 to recital 19 187 for, 442 against, 16 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendments 409 + 417 (voted as one) to Annex VII, Part C, point 16 208 for, 431 against, 7 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 371 to Annex VII, Part C, point 13 530 for, 112 against, 4 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendments 408 + 416 (voted as one) to Annex VII, Part C, point 6 204 for, 438 against, 8 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 407 to Annex VII, Part C, point 4 137 for, 447 against, 61 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 318 to Article 55, après le paragraph 2 512 for, 120 against, 14 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 390 to Article 55, après le paragraph 2 105 for, 538 against, 3 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 389 to Article 38, paragraph 3, après le point b 96 for, 549 against, 3 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 388 to Article 18, paragraph 1 124 for, 515 against, 7 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 387 to Article 7, après le paragraph 4 207 for, 431 against, 10 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 137 to Article 6, paragraph 3, alinéa 1 — part 2 451 for, 182 against, 10 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 137 to Article 6, paragraph 3, alinéa 1 — part 1 461 for, 185 against, 5 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 394 to Article 6, paragraph 1, après l'alinéa 2 142 for, 496 against, 8 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 403 to Article 6, paragraph 1, alinéa 2 192 for, 442 against, 11 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 130 to Article 6, paragraph 1, alinéa 1 444 for, 189 against, 14 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 402 to Article 6, paragraph 1, alinéa 1 194 for, 434 against, 15 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 393 to Article 6, paragraph 1, alinéa 1 120 for, 529 against, 2 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 150 to Article 6 — part 2 438 for, 196 against, 8 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 150 to Article 6 — part 1 452 for, 195 against, 2 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 134 to Article 6 473 for, 154 against, 22 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 133 to Article 6 — part 2 512 for, 122 against, 15 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 133 to Article 6 — part 1 505 for, 126 against, 19 abstainedPosition: For Majority line: For
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 401 to Article 6 131 for, 447 against, 72 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 392 to Article 4, après le paragraph 1 138 for, 504 against, 4 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 391 to Article 4, paragraph 1, après le point b 138 for, 508 against, 2 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendments 399 + 412 (voted as one) to Article 3, paragraph 1, point 15 168 for, 445 against, 36 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 398 to Article 3, paragraph 1, après le point 9 199 for, 437 against, 11 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 397 to Article 3, paragraph 1, point 9 158 for, 471 against, 17 abstainedPosition: Against Majority line: Against
9 Sept 2025Circularity requirements for vehicle design and management of end-of-life vehicles Amendment 396 to Article 2, paragraph 6, partie introductive 197 for, 418 against, 30 abstainedPosition: Against Majority line: Against
8 Sept 2025Wednesday’s agenda – Request by the PPE Group Ordre du jour de mercredi — Demande du groupe PPE 384 for, 10 against, 51 abstainedPosition: For Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Final vote — text as a wholeAdopted 523 for, 75 against, 14 abstainedPosition: Against Majority line: Against
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 1 to paragraph 14 157 for, 428 against, 36 abstainedPosition: Against Majority line: Against
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 8, adding text after paragraph 13 95 for, 420 against, 119 abstainedPosition: For Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Paragraph 13 — part 2 483 for, 84 against, 67 abstainedPosition: Against Majority line: Against
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 7 to paragraph 13 80 for, 407 against, 151 abstainedPosition: For Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 6, adding text after paragraph 12 79 for, 531 against, 18 abstainedPosition: For Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 5 to paragraph 10 47 for, 560 against, 27 abstainedPosition: For Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 4 to paragraph 8 88 for, 520 against, 22 abstainedPosition: For Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 3, adding text after paragraph 2 63 for, 552 against, 15 abstainedPosition: For Majority line: For
10 Jul 2025Tackling China’s critical raw materials export restrictions Amendment 2, adding text after paragraph 1 123 for, 390 against, 110 abstainedPosition: For Majority line: For
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Final vote — text as a wholeAdopted 494 for, 83 against, 71 abstainedPosition: Against Majority line: Against
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Amendment 2, adding text after recital S 217 for, 409 against, 23 abstainedPosition: Against Majority line: Against
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Amendment 1, adding text after citation 2 226 for, 409 against, 17 abstainedPosition: Against Majority line: Against
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Paragraph 34 — part 2 566 for, 60 against, 23 abstainedPosition: Against Majority line: Against
10 Jul 2025Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness Paragraph 32 — part 1 588 for, 56 against, 7 abstainedPosition: Against Majority line: Against

Show all 50 votes on this page

Roll-call participation

One cell per sitting while in office, shaded by the share of that day’s roll calls the member voted in. The official attendance register is kept separately by Parliament.

No vote recorded on 3 of 80 sittings with roll calls.

"No vote recorded" is not the same as absent: leave, illness and chairing the sitting look the same.

Data as a table

Voting neighbours

Members who voted the same way most often in the roll calls they both took part in, within and outside the member’s group (group at the date of each vote), over all roll calls of the term.

At least 200 shared roll calls over at least six months in office together. Within = both sat in the same group on the date of the vote; a member who changed group can appear on both lists. Baseline = the median agreement of all pairs of members of the groups the two sat in on the date of each shared vote (within: the group they shared; outside: the two groups), weighted by the votes they shared in each combination.

Within The Left

Agreement: roll calls where both cast the same position, of the roll calls both voted in while in the same group (“shared”); a count below 50 shared. Baseline: the median agreement of every pair of members of that group.
SelectMemberGroupCountryAgreementBaseline
Marina MESURE The LeftFrance100 % of 5 309 shared87 %
Arash SAEIDI The LeftFrance100 % of 4 348 shared87 %
Rima HASSAN The LeftFrance100 % of 4 302 shared87 %
Emma FOURREAU The LeftFrance100 % of 4 971 shared87 %
Leila CHAIBI The LeftFrance100 % of 5 252 shared87 %
Damien CARÊME The LeftFrance99 % of 4 791 shared87 %
Manon AUBRY The LeftFrance98 % of 5 237 shared87 %
Younous OMARJEE The LeftFrance95 % of 3 881 shared87 %
Mimmo LUCANO The LeftItaly94 % of 2 286 shared87 %
Ilaria SALIS The LeftItaly93 % of 4 568 shared87 %

Show all 10 neighbours

Outside the group

Agreement: roll calls where both cast the same position, of the roll calls both voted in while in different groups (“shared”); a count below 50 shared. Baseline: the median agreement of every pair of members of the groups the two sat in on those votes (groups at the date, weighted by the votes shared in each combination).
SelectMemberGroupCountryAgreementBaseline
Ana MIRANDA PAZ GreensSpain87 % of 4 518 shared77 %
Vicent MARZÀ IBÁÑEZ GreensSpain85 % of 4 898 shared77 %
Benedetta SCUDERI GreensItaly84 % of 5 146 shared77 %
David CORMAND GreensFrance84 % of 5 216 shared77 %
Mélissa CAMARA GreensFrance84 % of 4 818 shared77 %
Cristina GUARDA GreensItaly84 % of 4 465 shared77 %
Saskia BRICMONT GreensBelgium84 % of 5 010 shared77 %
Leoluca ORLANDO GreensItaly83 % of 4 611 shared77 %
Marie TOUSSAINT GreensFrance83 % of 5 035 shared77 %
Jaume ASENS LLODRÀ GreensSpain83 % of 4 345 shared77 %

Show all 10 neighbours

Work

Seats in committees, delegations and intergroups, and the dossiers the member leads, shadows or negotiates.

Seats

Body: the committee, delegation or intergroup, with its kind. Role: the member’s role in it. From, To: the dates of the seat (“now” while it lasts).
BodyRoleFromTo
Committee on Constitutional AffairsAFCO CommitteeMember19 Jul 2024now
Committee on Culture and EducationCULT CommitteeSubstitute19 Jul 2024now
Committee on Industry, Research and EnergyITRE CommitteeMember19 Jul 2024now
Delegation for relations with the countries of the Andean CommunityDAND DelegationMember19 Sept 2024now
Delegation to the Euro-Latin American Parliamentary AssemblyDLAT Parliamentary assemblyMember7 Oct 2024now
Intergroup on Anti-CorruptionIG10-01 Intergroup / working groupVice-chair16 Jan 2025now
Intergroup on Fighting against PovertyIG10-12 Intergroup / working groupMember24 Jan 2025now
Intergroup on the Social Economy and Services of General InterestIG10-23 Intergroup / working groupMember30 Jan 2025now
Intergroup on Trade UnionsIG10-24 Intergroup / working groupMember31 Jan 2025now
Delegation to the Euro-Latin American Parliamentary AssemblyDLAT Parliamentary assemblySubstitute19 Sept 20246 Oct 2024

Show all 10 seats

Dossiers

Dossier: the procedure the declaration names (“No dossier named” for a delegation without one). Role: rapporteur, shadow rapporteur, negotiator or delegation. Committee: the committee that appointed them. Date: of the declaration.
DossierRoleCommitteeDate
No dossier namedDelegation vice-chairDAND8 Jul 2026
Permanent system for the allocation of seats in the European ParliamentShadow rapporteurAFCO6 Jul 2026
Boosting skills in the Union – opportunities for vocational education and training in times of transitionShadow rapporteur for an opinionCULT23 Jun 2026
A compass for Global Gateway in a world of crises - further guidance for core instruments, flagship projects and the Team Europe approachShadow rapporteur for an opinionCULT23 Jun 2026
The Institutional Framework of the European Union and its interaction with national authorities in the application of Union law, with particular reference to Article 19 TEUShadow rapporteurAFCO8 May 2026
Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act)Shadow rapporteurITRE23 Mar 2026
Financial literacy and the rise of finfluencers in the context of the savings and investments unionShadow rapporteur for an opinionCULT1 Dec 2025
Establishing the European Social Fund as part of the National and Regional Partnership Plan set out in Regulation (EU) […] [NRPPlan] establishing conditions for the implementation of the Union support to quality employment, skills and social inclusion for the period from 2028 to 2034Shadow rapporteur for an opinionCULT17 Nov 2025
Amending Council Regulation (EU) 2021/1173 of 13 July 2021 on establishing the European High Performance Computing Joint Undertaking and repealing Regulation (EU) 2018/1488Shadow rapporteurITRE21 Oct 2025
mission to EcuadorOfficial delegationDAND4 Sept 2025

Show all 23 dossier roles

Topics they work on (model-assigned)

Counts: dossiers they spoke on, led or amended, and their questions and motions.

In the chamber

Speeches and statements in plenary debates, newest first; the verbatim report is on Parliament’s site.

39 contributions recorded; 7 on behalf of their group; 44 minutes of speaking time.

Show all 39 recent contributions

Questions and motions, 143

Parliamentary questions and motions for resolutions the member authored or co-signed, newest first.

Date: tabled. Title: the question or motion, with its id. Kind: written question or motion for a resolution, with the number of co-authors. Answer: the date of the answer to a question.
DateTitleKindAnswer
18 Sept 2026Combating serophobia and the European regulatory framework against HIV-related discrimination E-10-2026-003750Written questionNot yet answered
13 Sept 2026Repeated ban on Oradea Pride and compliance with fundamental rights in the use of EU funds E-10-2026-003648Written questionwith 17 co-authorsNot yet answered
7 Sept 2026Climate change, public health and the world of work: for a directive on maximum working temperatures O-10-2026-000035Oral questionwith 35 co-authorsNot yet answered
22 Jul 2026MOTION FOR A RESOLUTION on tackling vulture funds in the European Union B-10-2026-0370Motion for a resolution—
17 Jul 2026Stepping up capacity to build water-bomber aircraft in the EU E-10-2026-003039Written question28 Aug 2026
17 Jul 2026Prison conditions exacerbated by the heatwave in Europe E-10-2026-003048Written question25 Sept 2026
17 Jul 2026Official recognition of a European Day in Remembrance of the Victims of Accidents at Work E-10-2026-003042Written question21 Aug 2026
16 Jul 2026Israeli interference in French elections and European election campaigns E-10-2026-003012Written questionwith 2 co-authorsNot yet answered
14 Jul 2026Continued implementation of the peace accord given the advent of the extreme right government in Colombia E-10-2026-002914Written question17 Aug 2026
13 Jul 2026Consistency between EU industrial decarbonisation funding and the EU’s restrictive measures: the case of ROCKWOOL E-10-2026-002886Written questionNot yet answered

Show all 143 questions and motions

Amendments tabled in committee, 51

Committee amendment documents that carry amendments by the member, with how many are theirs.

Date: of the amendment document. Text amended: the dossier and the document’s id. Committee: where the amendments were tabled. Amendments: how many in the document are the member’s.
DateText amendedCommitteeAmendments
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790932 CJ5314
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790938 CJ5318
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790937 CJ5314
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790005 CJ5319
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790953 CJ5327
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790933 CJ5316
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790935 CJ5317
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790936 CJ538
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790939 CJ5317
13 Jul 2026Establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health and amending Regulations (EC) No 178/2002, (EC) No 1394/2007, (EU) No 536/2014, (EU) 2019/6, (EU) 2024/795 and (EU) 2024/1938 (European Biotech Act) CJ53-AM-790934 CJ5319

Show all 51 amendment documents

Connections

Dossiers they lead or shadow, committees, party, delegation and other related pages.

Political group

National delegation

  • Delegation France National delegation

Sources & citation

Where the facts on this page come from, and how to cite it.

Data source
Licensed CC BY 4.0.
Data version
data version 343d33dd3e67 (2 Oct 2026) · methods: group-at-date v1, participation v1, abstention v1, loyalty v1, against-clear v1, cohesion v1, agreement v1, group-agreement v1, winning-side v1, similar-votes v1, scope v1, data-version v1 · methods
Retrieved
2 October 2026

Cite as

EU Parl Watch Research (2026). “Anthony SMITH”. Member record. memberId 256910. EU Parl Watch Research. https://news.eu-parl.st-solutions.dev/members/256910?page=77&scope=final&vscope=all (retrieved 2 October 2026). Official source: Member’s profile, European Parliament, https://www.europarl.europa.eu/meps/en/256910. Data: EP Open Data: member record, https://data.europarl.europa.eu/api/v2/meps/256910?format=application%2Fld%2Bjson (CC BY 4.0); data version 343d33dd3e67 (2 Oct 2026) · methods: group-at-date v1, participation v1, abstention v1, loyalty v1, against-clear v1, cohesion v1, agreement v1, group-agreement v1, winning-side v1, similar-votes v1, scope v1, data-version v1.
BibTeX
@misc{epw-member-256910,
  author = {{EU Parl Watch Research}},
  title = {{Anthony SMITH}},
  year = {2026},
  howpublished = {\url{https://news.eu-parl.st-solutions.dev/members/256910?page=77&scope=final&vscope=all}},
  url = {https://news.eu-parl.st-solutions.dev/members/256910?page=77&scope=final&vscope=all},
  urldate = {2026-10-02},
  publisher = {EU Parl Watch Research},
  note = {Member record. memberId 256910. Official source: https://www.europarl.europa.eu/meps/en/256910. Data: EP Open Data: member record (CC BY 4.0); data version 343d33dd3e67 (2 Oct 2026) · methods: group-at-date v1, participation v1, abstention v1, loyalty v1, against-clear v1, cohesion v1, agreement v1, group-agreement v1, winning-side v1, similar-votes v1, scope v1, data-version v1}
}